tldrdailynews.com logo

Retatrutide delivers unprecedented weight loss in obesity Phase 3 trial

1 min read
Source: The Guardian
Retatrutide delivers unprecedented weight loss in obesity Phase 3 trial
Photo: The Guardian
TL;DR

Eli Lilly's retatrutide, a weekly triple hormone receptor agonist (GLP-1, GIP, glucagon), produced an average 28.3% weight loss (70.3 lb) over 80 weeks at the 12 mg dose in a Phase 3 trial of 2,339 adults with obesity or overweight and a weight-related comorbidity. The 12 mg group lost more weight than the 9 mg and 4 mg groups, with 65.3% reaching a BMI below 30 and 37.5% starting with BMI ≥40; 45.3% achieved at least 30% weight loss. Retatrutide’s weight loss appears to exceed current drugs Wegovy and Zepbound. The drug, which combines GLP-1 and GIP with glucagon, also improved cardio-metabolic risk factors, though side effects such as nausea, diarrhea, constipation, and vomiting increased with dose.

Topics:businesshealth#glp-1#glucagon#health#obesity#retatrutide#weight-loss
Share this article
  1. New weight-loss shot appears to outperform other obesity drugs on market  The Guardian
  2. Experimental Drug Yields Dramatic Weight Loss  The New York Times
  3. Eli Lilly says next-generation weight loss drug clears crucial obesity trial  CNBC
  4. New weight-loss shot more powerful than old GLP-1s, Eli Lilly says  USA Today
  5. Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial  PR Newswire

Want the full story? Read the original reporting

Read on The Guardian